Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
January 4, 2018
Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
December 11, 2017
Revance Announces Closing of Public Offering of Common Stock
December 7, 2017
Revance Announces Pricing of Public Offering of Common Stock
December 5, 2017
Revance Announces Proposed Public Offering of Common Stock
December 5, 2017
Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
November 29, 2017
Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia
November 20, 2017
Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia
November 2, 2017
Revance Releases Third Quarter 2017 Results
October 18, 2017
Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
October 18, 2017
Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
Displaying 181 - 190 of 298